For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

As a mass rollout of weight loss injections begins across the NHS, with GPs able to prescribe Mounjaro for the first time ...

A recent study found that oral semaglutide offers meaningful cardiovascular benefits for people with type 2 diabetes, lowering risk by 14%. Results from the Semaglutide Cardiovascular Outcomes Trial ...

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal antibody that binds to and inhibits activin receptor type-2B, with semaglutide ...

Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Mounjaro was launched in India earlier this year, while many leading multinational pharma companies are in the race to ...

How long does Ozempic stay in your system? What to expect after stopping, including clearance time, side effects, and factors that influence it.